Pulmonary mycobacteriosis caused by Mycobacterium peregrinum
A case report
Yutaka Morita, MDa,b, Yoshihiro Kondo, MDa, Eiji Takeuchi, MD, PhDc,*

Abstract
Rationale: Mycobacterium peregrinum is a member of the group of rapidly growing nontuberculous mycobacteria. It mainly causes surgical site and catheter-related infections, while pulmonary infection is rare. We herein present a case of pulmonary infection caused by M peregrinum.

Patient concerns: A 62-year-old woman visited our hospital with dyspnea and was admitted for the treatment of pneumonia in July 2018.

Diagnosis: Chest computed tomography showed patchy opacities and consolidation in the bilateral lungs and a cavity in the right upper lobe, which persisted after the treatment of bacterial pneumonia 5 years ago. She was administered ceftriaxone and azithromycin. Consolidation in the bilateral lungs improved, whereas the cavity in the right upper lobe remained and the consolidation surrounding it gradually spread. On admission, the sputum acid-fast bacillus culture was positive, and M peregrinum was identified twice by mass spectrometry. The cavity and consolidation surrounding it were diagnosed as pulmonary mycobacteriosis caused by M peregrinum.

Interventions: Although we recommended treatment for mycobacteriosis, the patient refused it.

Outcomes: The patient is regularly followed up; however, the cavity wall is thickening and shadows have become mildly enhanced over the course of 3 years.

Lessons: We herein present a rare case of pulmonary mycobacteriosis caused by M peregrinum and discuss the literature. Since limited information is currently available on pulmonary mycobacteriosis caused by M peregrinum, the accumulation of further case reports and the clarification of its clinical features are needed.

Abbreviations: CT = computed tomography, NTM = nontuberculous mycobacteria, RGM = rapidly growing nontuberculous mycobacteria.

Keywords: Mycobacterium peregrinum, nontuberculous mycobacteria, pulmonary mycobacteriosis, rapidly growing nontuberculous mycobacteria

1. Introduction

Among nontuberculous mycobacteria (NTM), rapidly growing nontuberculous mycobacteria (RGM) are mainly reported as pathogens in lung, skin, soft tissue, and bone infections. They are generally classified into a number of groups including the Mycobacterium fortuitum group, Mycobacterium chelonae abscessus group, and Mycobacterium mucogenicum group. Mycobacterium peregrinum has been classified into the M fortuitum group and accounts for approximately 2% of RGM infections.11 Although it mainly causes surgical site and catheter-related infections, only a small number of cases have been reported to date. Lung infections caused by M peregrinum are even rarer and, thus, its clinical features remain unknown and there is currently no established treatment. We herein present a rare case of pulmonary mycobacteriosis caused by M peregrinum.

2. Case report

A 62-year-old woman visited our hospital with dyspnea in July 2018. She had a medical history of bronchial asthma and had inhaled budesonide/formoterol. In 2013, she had a negative sputum mycobacteria test and was treated for bacterial pneumonia. Her smoking history was 15 pack-years, and she...
was a current smoker. Her physical examination showed a body temperature of 36.8°C, heart rate of 119 beats per minute, blood pressure of 162/100 mm Hg, percutaneous oxygen saturation of 94% on 2 L/min oxygen with a nasal cannula, and respiratory rate of 28 breaths per minute. Chest auscultation revealed coarse crackles on both of the lower sides and normal heart sounds without murmurs. Laboratory examinations (Table 1) showed a white blood cell count of 11,860/μL with 89.1% neutrophils, hemoglobin of 13.3 g/dL, a platelet count of 30.4 × 10⁴/μL, blood urea nitrogen of 23 mg/dL, creatinine of 0.84 mg/dL, and C-reactive protein of 35.01 mg/dL. Chest X-ray revealed consolidation in the bilateral lower lung fields and a cavity in the right upper lung field (Fig. 1A). Chest computed tomography (CT) showed consolidation in the middle lobe, patchy opacities in both lower lobes, and a cavity with a diameter of 30 to 47 mm in the upper right lobe (Fig. 1B–E). There was no calcification or lymphadenopathy. The cavity in the right upper lobe persisted. We decided to discharge the patient with follow-ups at the outpatient department. Three months after discharge, CT confirmed that consolidation surrounding the cavity in the right upper lobe had spread (Fig. 2). The patient was diagnosed with pulmonary mycobacteriosis caused by M. peregrinum. Although the patient received a full explanation and we recommended treatment for mycobacteriosis, she refused this course of action. Therefore, we continue to periodically follow-up the patient. The cavity wall is thickening and the shadows have become mildly enhanced over the course of 3 years.

### 3. Discussion

RGM, called Runyon classification Group IV, are defined as species that colonize and achieve mature growth on pure cultures within 7 days. They are generally classified into 6 groups: the M sputum mycobacterial smear tests was positive (Gaffky scale 2). Both sputum samples were subsequently positive in liquid cultures. M. peregrinum was identified by mass spectrometry. Isolated M. peregrinum showed a low minimal inhibitory concentration for levofloxacin and clarithromycin. Consolidation in both lungs improved with the administration of ceftriaxone for 15 days and azithromycin for 3 days; however, the cavity in the right upper lobe persisted. We decided to discharge the patient with follow-ups at the outpatient department. Three months after discharge, CT confirmed that consolidation surrounding the cavity in the right upper lobe had spread (Fig. 2). The patient was diagnosed with pulmonary mycobacteriosis caused by M. peregrinum. Although the patient received a full explanation and we recommended treatment for mycobacteriosis, she refused this course of action. Therefore, we continue to periodically follow-up the patient. The cavity wall is thickening and the shadows have become mildly enhanced over the course of 3 years.

### Table 1

| Hematology    | Biochemistry     |
|---------------|------------------|
| WBC 11,860/μL | AST 23 U/L       |
| Neutro 89.1%  | ALP 26 U/L       |
| Lymph 4.6%    | LDH 231 U/L      |
| Mono 5.5%     | BUN 23 mg/dL     |
| Eosin 0.0%    | Cre 0.84 mg/dL   |
| Baso 0.8%     | Na 142 mEq/L     |
| RBC 427 × 10⁴ | K 4.2 mEq/L      |
| Hb 13.3 g/dL  | Cl 107 mEq/L     |
| Pt 30.4 × 10⁴ | TP 6.4 mg/dL     |

| Serology      | Infection        |
|---------------|------------------|
| CRP 35.01 mg/dL | MAC Ab 0.72 U/mL |
| B-D-glucan 5.4 pg/mL |                |

BUN = blood urea nitrogen, CRP = C-reactive protein.

---

Figure 1. Chest X-ray (A) and chest computed tomography (CT) findings (B–E) on admission. A: Chest X-ray shows a cavity in the right upper lung field and consolidation in the bilateral lower lung fields. B–E: CT scanning shows a cavity in the upper right lobe, consolidation in the middle lobe, and patchy opacities in both lower lobes.
fortuitum group, M chelonae abscessus group, M mucogenicum group, Mycobacterium mageritense group, Mycobacterium smegmatis group, and early pigmented rapidly growing mycobacteria. The *M fortuitum* group consists of *M fortuitum*, *M peregrinum*, *Mycobacterium houstonense*, and *Mycobacterium porcinum*. Since some cases of infection by the *M fortuitum* group have been reported together as infection by *M fortuitum*, only a few cases of *M peregrinum* have been described to date and, thus, its clinical features remain unclear.

The *M fortuitum* group is found in soil and water, including tap water and hospital water systems. To the best of our knowledge, there have been 20 case reports related to *M peregrinum* causing infections in surgical sites, cardiac devices, soft tissue, central catheters, and the lungs, including the present case (Table 2). Among these cases, 11 (55%) were male and the age at diagnosis ranged between 1 to 83 years. Elderly patients with pre-existing lung diseases, such as a previous history of lung tuberculosis and bronchiectasis, are susceptible to pulmonary

![Figure 2. Chest computed tomography findings 3 months after diagnosis. A, B: Consolidation surrounding the cavity in the right upper lobe spread. C, D: Consolidation and patchy opacities in the bilateral lower lobes improved.](image)

### Table 2

| Case | Age/sex | Site of infection         | Antibiotics          | Ref |
|------|---------|---------------------------|----------------------|-----|
| 1    | 74/M    | AICD                      | CPFX, CAM            | [3] |
| 2    | 59/F    | Pacemaker                 | MFLX, S/T            | [4] |
| 3    | 75/M    | Pacemaker                 | CPFX, CAM            | [5] |
| 4    | 17/F    | Prosthetic aortic valve   | CAM, AMK, IMP/CS, DOXY, S/T, RFP | [6] |
| 5    | 38/M    | Hickman catheter          | VCM                  | [7] |
| 6    | 2/M     | Lymph node                | CPFX, CAM, AMK       | [8] |
| 7    | 1/M     | Lymph node                | CPRM, IMP/CS         | [9] |
| 8    | 13/F    | Skin and soft tissue      | NA                   | [10]|
| 9    | 58/F    | Surgical site             | LVFX, AMK, IMP/CS    | [11]|
| 10   | 30/F    | Tonsillar abscess         | CAM, IMP/CS, FRPM    | [12]|
| 11   | 83/M    | Skin and soft tissue      | MINO                 | [13]|
| 12   | 45/M    | Skin and soft tissue      | SPPX, MINO           | [14]|
| 13   | 40/M    | Skin and soft tissue      | CPFX, CAM, AMK       | [15]|
| 14   | 30/F    | Skin and soft tissue      | CPFX, CAM, IMP/CS    | [16]|
| 15   | 40/F    | Pneumonia                 | CPFX, CAM            | [17]|
| 16   | 24/M    | Pneumonia                 | LVFX, CAM, EB        | [18]|
| 17   | 61/F    | Pneumonia                 | LVFX, CAM, MINO      | [19]|
| 18   | 72/M    | Pneumonia                 | EB, RFP, PZA, INH    | [20]|
| 19   | 68/M    | Pneumonia                 | EB, RFP, PZA, INH    | [21]|
| This case | 62/F | Pneumonia | No treatment | |

AICD = automatic implantable cardioverter defibrillator, AMK = amikacin, CAM = clarithromycin, CPFX = ciprofloxacin, CPRM = capreomycin, DOXY = doxycycline, EB = ethambutol, FRPM = faropenem, IMP/CS = imipenem/cilastatin sodium, INH = isoniazid, LVFX = levofloxacin, MFLX = moxifloxacin, MINO = minocycline, NA = not available, PZA = pyrazinamide, RFP = rifampicin, S/T = sulfamethoxazole/trimethoprim, SPPX = sparfloxacin, VCM = vancomycin.
mycobacteriosis by the *M. fortuitum* group. However, a young man without any underlying diseases was also reported to have pulmonary infection caused by *M. peregrinum*. There are no marked differences in symptoms from other NTM groups, such as chronic cough, sputum, fever, and weight loss. The CT findings of pulmonary mycobacteriosis by the *M. fortuitum* group show multiple small nodules, patchy shadows, and bronchiectasis. Although cavity lesions are rare, 1 case in which infection caused by *M. peregrinum* formed a cavity has been reported. In the present case, radiographic imaging revealed a cavity in the right upper lobe; however, it was not unclear whether this was due to *M. peregrinum* infection or previous pneumonia. The *M. fortuitum* group is particularly apt at contaminating water systems, and a previous study described mass infections of soft tissues from a foot bath. Therefore, it is diagnostically necessary to establish whether *M. peregrinum* detected in just 1 sample is a contaminant or a pathogen. The American Thoracic Society-Infectious Diseases Society of America guidelines for NTM infections states that positive cultures need to be obtained from 2 separate samples of expectorated sputum. We diagnosed the present case from 2 positive sputum cultures and typical CT images. There have been 5 case reports of pulmonary mycobacteriosis caused by *M. peregrinum*, and only 2 were diagnosed from 2 positive sputum samples.

The treatment of *M. peregrinum* is not described in the official guidelines. Isolates of *M. fortuitum* are generally susceptible to macrolides (clarithromycin and azithromycin), quinolones (ciprofloxacin, levofloxacin, and moxifloxacin), sulfonamides, linezolid, imipenem, doxycycline, cefoxitin, and aminoglycosides. In the treatment of lung disease caused by *M. fortuitum*, at least 2 antibacterial agents from these agents with in vitro activity need to be administered for at least 12 months until sputum cultures become negative. *M. fortuitum* isolates contain an inducible erm (39) gene that confers resistance to macrolides. Therefore, macrolides need to be administered with caution. Among 20 cases of *M. peregrinum* infection, quinolones were used to treat 11 (55%), macrolides for 9 (45%), aminoglycosides for 6 (30%), carbapenems for 6 (30%), and tetracyclines for 4 (20%). In 5 cases of lung disease caused by *M. peregrinum*, 2 were treated with rifampicin, isoniazid, pyrazinamide, and ethambutol, 1 with clarithromycin and ciprofloxacin, and 2 with clarithromycin, levofloxacin, and ethambutol/minocycline. Good treatment responses were achieved, excluding a case of polymyositis treated with infliximab. Since consolidation around the cavity gradually spread in the present case, we recommended treatment with 2 or more antibacterial agents, including the newer macrolides and quinolones. However, the patient refused this treatment. Therefore, we continue to periodically follow-up the patient. The cavity wall is thickening and the shadows have become mildly enhanced over the course of 3 years.

4. Conclusion

Limited information is currently available on pulmonary mycobacteriosis caused by *M. peregrinum* and, thus, the accumulation of further case reports and the clarification of its clinical features are needed.

**Author contributions**

**Conceptualization:** Eiji Takeuchi.

**Data curation:** Yutaka Morita, Yoshihiro Kondo.

**Formal analysis:** Yutaka Morita.

**Resources:** Yutaka Morita, Yoshihiro Kondo.

**Visualization:** Yutaka Morita.

**Writing – original draft:** Yutaka Morita.

**Writing – review & editing:** Eiji Takeuchi.

**References**

1. Brown-Elliot BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002;15:716–46.

2. Galassi L, Donato R, Tortoli E, et al. Nontuberculous mycobacteria in hospital water systems: application of HPLC for identification of environmental mycobacteria. J Water Health 2003;1:133–9.

3. Short WR, Emery C, Bhandary M, et al. Misidentification of *Mycobacterium peregrinum*, the causal organism of a case of bacteremia and automatic implantable cardioverter defibrillator-associated infection, due to its unusual acid-fast staining characteristics. J Clin Microbiol 2005;43:2015–7.

4. Chrissoheris MP, Kadakia H, Mariie M, et al. Pacemaker pocket infection due to *Mycobacterium goodii*: case report and review of the literature. Conn Med 2008;72:6–7.

5. Amareou S, Tsexier-Maure J, Bordachar P. PET scan in suspected but unproven pacemaker endocarditis. Arch Cardiovasc Dis 2012;105:125–6.

6. Torres-Duque CA, Diaz C, Vargas L, et al. Disseminated mycobacteriosis affecting a prostatic aortic valve: first case of *Mycobacterium peregrinum* type III reported in Colombia. Biomedica 2010;30:332–7.

7. Rodríguez-Gancedo MB, Rodríguez-González T, Yagüe G, et al. *Mycobacterium peregrinum* bacteremia in an immunocompromised patient with a Hickman catheter. Eur J Clin Microbiol Infect Dis 2001;20:589–90.

8. Tsoila MN, Chappier A, Taprantzi P, et al. Disseminated nontuberculous mycobacterial infection in a child with interferon-gamma receptor 1 deficiency. Eur J Pediatr 2006;165:458–61.

9. Koscielniak E, de Boer T, Dupuis S, et al. Disseminated *Mycobacterium peregrinum* infection in a child with complete interferon-gamma receptor-1 deficiency. Pediatr Infect Dis J 2003;22:378–80.

10. Pérez-Alfonzio R, Poloio Brito LE, Vergara MS, et al. Odontogenic cutaneous sinus tracts due to infection with nontuberculous mycobacteria: a report of three cases. BMC Infect Dis 2020;20:295.

11. Nagao M, Sonobe M, Bando T, et al. Surgical site infection due to *Mycobacterium goodii*: a case report and literature review. Int J Infect Dis 2009;13:208–11.

12. Sakai T, Kobayashi C, Shinohara M, et al. *Mycobacterium peregrinum* infection in a patient with AIDS. Intern Med 2005;44:266–9.

13. Kamijo F, Ubara H, Kubo H, et al. A case of mycobacterial skin disease caused by *Mycobacterium peregrinum*, and a review of cutaneous infection. Case Rep Dermatol 2012;7:6–9.

14. Ishii N, Sugita Y, Sato L, et al. A case of mycobacterial skin disease caused by *Mycobacterium peregrinum* and *M. scrofulaceum*. Acta Derm Venerol 1998;78:67–7.

15. Appelgren P, Farnebo F, Doterval I, et al. Late-onset posttraumatic skin and soft-tissue infections caused by rapidly-growing mycobacteria in tsunami survivors. Clin Infect Dis 2008;47:e1–6.

16. Pagnoux C, Nassif X, Boizard C, et al. Infection of continuous subcutaneous insulin infusion site with *Mycobacterium peregrinum*. Diabetes Care 1998;21:191–2.

17. Rolan N, Limongi L, Putruvee AM. *Mycobacterium peregrinum*: an atypical and uncommon mycobacterium. A case report. Arch Bronchoneumol (Engl Ed) 2020;56:311–2.

18. Sawahata M, Hagiwara E, Ogura T, et al. Pulmonary mycobacteriosis caused by *Mycobacterium peregrinum* in a young, healthy man. Nikhon Kokyu Gakkai Zasshi 2010;48:866–70.

19. Fujiwara K. A case of pulmonary infection caused by *Mycobacterium peregrinum*. Iryo 2008;62:281–4.

20. Todorova TT, Kaludova V, Tsankova G, et al. A pulmonary infection caused by *Mycobacterium peregrinum* – a case report. J IMAB 2015;4:161–7.

21. Marie I, Heliot P, Roussel F, et al. Fatal *Mycobacterium peregrinum* pneumonia in refractory polymyositis treated with infliximab. Rheumatology (Oxford) 2005;44:1201–2.

22. Jeong YJ, Lee KS, Koh WJ, et al. Nontuberculous mycobacterial pulmonary infection in immunocompetent patients: comparison of thin-section CT and histopathologic findings. Radiology 2004;231:880–6.
[23] Hagiwara E, Sekine A, Sato T, et al. Clinical features of pulmonary
disease caused by Mycobacterium fortuitum. Nihon Kokyuki Gakkai
Zasshi 2008;46:788–92.

[24] Winthrop KL, Abrams M, Yakrus M, et al. An outbreak of
mycobacterial furunculosis associated with footbaths at a nail salon.
N Engl J Med 2002;346:1366–71.

[25] Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA
statement: diagnosis, treatment, and prevention of nontuberculous
mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367–416.

[26] Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility
testing, drug resistance mechanisms, and therapy of infections with
nontuberculous mycobacteria. Clin Microbiol Rev 2012;25:545–82.